HomeCompareBTKRF vs ABBV

BTKRF vs ABBV: Dividend Comparison 2026

BTKRF yields 2096.44% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTKRF wins by $15421713801.65M in total portfolio value
10 years
BTKRF
BTKRF
● Live price
2096.44%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15421713801.75M
Annual income
$14,098,781,179,144,216.00
Full BTKRF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — BTKRF vs ABBV

📍 BTKRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTKRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTKRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTKRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTKRF
Annual income on $10K today (after 15% tax)
$178,197.06/yr
After 10yr DRIP, annual income (after tax)
$11,983,964,002,272,584.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, BTKRF beats the other by $11,983,964,002,251,058.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTKRF + ABBV for your $10,000?

BTKRF: 50%ABBV: 50%
100% ABBV50/50100% BTKRF
Portfolio after 10yr
$7710856900.93M
Annual income
$7,049,390,589,584,770.00/yr
Blended yield
91.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BTKRF
No analyst data
Altman Z
-3.7
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTKRF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTKRFABBV
Forward yield2096.44%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$15421713801.75M$103.7K
Annual income after 10y$14,098,781,179,144,216.00$25,324.79
Total dividends collected$15328151116.84M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BTKRF vs ABBV ($10,000, DRIP)

YearBTKRF PortfolioBTKRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$220,344$209,643.61$11,555$434.96+$208.8KBTKRF
2$4,552,929$4,317,161.50$13,485$635.47+$4.54MBTKRF
3$88,240,705$83,369,070.34$15,933$937.67+$88.22MBTKRF
4$1,604,495,117$1,510,077,563.33$19,118$1,400.80+$1604.48MBTKRF
5$27,378,479,433$25,661,669,657.38$23,384$2,125.24+$27378.46MBTKRF
6$438,529,301,103$409,234,328,109.88$29,290$3,286.81+$438529.27MBTKRF
7$6,595,234,522,110$6,126,008,169,929.44$37,776$5,205.38+$6595234.48MBTKRF
8$93,161,315,955,682$86,104,415,017,024.97$50,495$8,488.44+$93161315.91MBTKRF
9$1,236,385,628,606,484$1,136,703,020,533,904.00$70,497$14,346.44+$1236385628.54MBTKRF
10$15,421,713,801,753,156$14,098,781,179,144,216.00$103,718$25,324.79+$15421713801.65MBTKRF

BTKRF vs ABBV: Complete Analysis 2026

BTKRFStock

Q Precious & Battery Metals Corp. engages in the exploration of mineral properties in Canada. The company primarily explores for gold, lead, lithium, copper, nickel, cobalt, zinc, molybdenum, and platinum group elements. Q Precious & Battery Metals Corp. holds interest in various precious and critical elements projects located in Abitibi greenstone belt region of Val d'Or, Quebec.

Full BTKRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BTKRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTKRF vs SCHDBTKRF vs JEPIBTKRF vs OBTKRF vs KOBTKRF vs MAINBTKRF vs JNJBTKRF vs MRKBTKRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.